Immunotherapy for Alzheimer's disease: Will vaccination work?

Jean Cosme Dodart, Kelly R. Bales, Steven M. Paul

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Active or passive immunization against the β-amyloid peptide (Aβ) has been proposed as a method for preventing and/or treating Alzheimer's disease (AD). In addition to lowering brain Aβ and amyloid burden in transgenic mouse models of AD, a beneficial effect of immunization on previously characterized memory impairment(s) has also been reported in these mice. Whether these preclinical data will predict efficacy in AD patients remains to be seen. A clinical trial of active immunization (vaccination) was halted, owing to a serious adverse event (meningoencephalitis), raising questions about the safety of this approach. Two recent reports suggest that immunotherapy-based approaches to treating and preventing AD will require careful antigen and antibody selection, to maximize efficacy and minimize serious adverse events. However, given the potential efficacy of this approach, we believe that immunotherapy for AD should not be prematurely abandoned.

Original languageEnglish
Pages (from-to)85-87
Number of pages3
JournalTrends in Molecular Medicine
Issue number3
StatePublished - Mar 1 2003


Dive into the research topics of 'Immunotherapy for Alzheimer's disease: Will vaccination work?'. Together they form a unique fingerprint.

Cite this